{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:57:07Z","timestamp":1784649427455,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA is associated with adverse drug reactions. This study aimed to evaluate the adverse events (AEs) associated with MPA in by analyzing real-world data from the U.S. Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS). By providing a comprehensive assessment of the safety profile of MPA, this study seeks to support informed clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data covering the period from the first quarter of 2004 to the first quarter of 2024 were collected from the FAERS database. Disproportionality analyses were conducted using several statistical methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayesian geometric mean (EBGM). Additionally, time-to-onset (TTO) analysis was employed to quantify the signals of the MPA-associated AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A comprehensive dataset comprising 21,035,995 AE reports was compiled. Among these, 3,939 women reported using MPA as a contraceptive method. The reports covered 27 system organ classes (SOCs) and 25 high-frequency AE signals. Notably, significant AEs were identified, some of which were not previously detailed in the medication\u2019s prescribing information. Unforeseen significant AEs such as unintended pregnancy (n = 623; ROR, 6.65; ROR025, 6.1; \u03c7<jats:sup>2<\/jats:sup>, 2,482.38; PRR, 6.41; EBGM, 5.69; EBGM05, 5.29), bone pain (n = 35; ROR, 13.78; ROR025, 9.4; \u03c7<jats:sup>2<\/jats:sup>, 311.2; PRR, 13.75; EBGM, 10.59; EBGM05, 7.69), gait disturbance (n = 34; ROR, 2.82; ROR025, 1.99; \u03c7<jats:sup>2<\/jats:sup>, 37.31; PRR, 2.88; EBGM, 2.7; EBGM05, 2.02), dental caries (n = 15; ROR, 23.16; ROR025, 12.32; \u03c7<jats:sup>2<\/jats:sup>, 204.26; PRR, 23.14; EBGM, 15.23; EBGM05, 8.98), decrease in blood pressure (n = 15; ROR, 3.88; ROR025, 2.29; \u03c7<jats:sup>2<\/jats:sup>, 29.35; PRR, 3.88; EBGM, 3.63; EBGM05, 2.33), and osteonecrosis (n = 9; ROR, 23.44; ROR025, 10.36; \u03c7<jats:sup>2<\/jats:sup>, 123.67; PRR, 23.43; EBGM, 15.35; EBGM05, 7.75) were identified as AEs that were not previously outlined in the prescribing information of the medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings align with clinical observations, highlighting the emergence of previously unreported AE signals associated with MPA and their demographic and TTO characteristics. Further pharmaco-epidemiological studies are required to substantiate these observations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1491032","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T04:42:02Z","timestamp":1733892122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data"],"prefix":"10.3389","volume":"15","author":[{"given":"Luyang","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13643-023-02216-2","article-title":"Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review","volume":"12","author":"Aderoba","year":"2023","journal-title":"Syst. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ecl.2012.04.006","article-title":"Pathophysiology of osteoporosis: new mechanistic insights","volume":"41","author":"Armas","year":"2012","journal-title":"Endocrinol. Metabolism Clin. N. Am."},{"key":"B3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/joim.13705","article-title":"The GABA system, a new target for medications against cognitive iMPAirment\u2014associated with neuroactive steroids","volume":"294","author":"B\u00e4ckstr\u00f6m","year":"2023","journal-title":"J. Intern. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e936727","DOI":"10.12659\/msm.936727","article-title":"Medroxyprogesterone acetate for abnormal uterine bleeding due to ovulatory dysfunction: the effect of 2 different-duration regimens","volume":"28","author":"Bender","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rehab.2016.09.002","article-title":"Stress, anxiety and depression in heart disease patients: a major challenge for cardiac rehabilitation","volume":"60","author":"Chauvet-Gelinier","year":"2017","journal-title":"Ann. Phys. Rehabilitation Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1417661","DOI":"10.3389\/fphar.2024.1417661","article-title":"Mining and evaluation of adverse event signals for capmatinib based on the FAERS database","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bmj.303.6793.13","article-title":"Bone density in women receiving depot medroxyprogesterone acetate for contraception","volume":"303","author":"Cundy","year":"1991","journal-title":"Bmj"},{"key":"B8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11904-023-00662-0","article-title":"Update on the impact of depot medroxyprogesterone acetate on vaginal mucosal endpoints and relevance to sexually transmitted infections","volume":"20","author":"Dabee","year":"2023","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cancers16193362","article-title":"The association between medroxyprogesterone acetate exposure and meningioma","volume":"16","author":"Griffin","year":"2024","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/sj.bdj.2014.905","article-title":"Drugs, medications and periodontal disease","volume":"217","author":"Heasman","year":"2014","journal-title":"Br. Dent. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11906-016-0642-9","article-title":"Hypertension, blood pressure variability, and target organ lesion","volume":"18","author":"Irigoyen","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/GME.0000000000002086","article-title":"The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials","volume":"30","author":"Jiang","year":"2023","journal-title":"Menopause (New York, N.Y.)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2018","journal-title":"Osteoporos. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"CD006133","DOI":"10.1002\/14651858.CD006133.pub5","article-title":"Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus","volume":"2019","author":"Lopez","year":"2019","journal-title":"Cochrane database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e10446","DOI":"10.1002\/jbm4.10446","article-title":"Bone mineral density in antiretroviral therapy\u2010na\u00efve HIV\u20101\u2013Infected young adult \u2010women using depot medroxyprogesterone acetate or nonhormonal contraceptives in Uganda","volume":"5","author":"Matovu","year":"2020","journal-title":"JBMR Plus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.contraception.2019.12.009","article-title":"An exploratory study of depot-medroxyprogesterone acetate and bone mineral density in adolescent and young adult womenwith cerebral palsy","volume":"101","author":"Roden","year":"2020","journal-title":"Contraception"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e078078","DOI":"10.1136\/bmj-2023-078078","article-title":"Use of progestogens and the risk of intracranial meningioma: national case-control study","volume":"384","author":"Roland","year":"2024","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"E1218","DOI":"10.1503\/cmaj.202413","article-title":"Adolescent contraception","volume":"193","author":"Rosenthal","year":"2021","journal-title":"Can. Med. Assoc. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","article-title":"The menopause transition: signs, symptoms, and management options","volume":"106","author":"Santoro","year":"2021","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12905-021-01178-8","article-title":"Anthropometric indices, blood pressure, and lipid profile status among women using progestin-only contraceptives: comparative cross-sectional study","volume":"21","author":"Shiferaw","year":"2021","journal-title":"BMC Women\u2019s Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/13625187.2019.1709963","article-title":"Depo-medroxyprogesterone acetate, weight gain and amenorrhea among obese adolescent and adult women","volume":"25","author":"Sims","year":"2020","journal-title":"Eur. J. Contracept. Reproductive Health Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/jog.16038","article-title":"Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"50","author":"Tamauchi","year":"2024","journal-title":"J. Obstetrics Gynaecol. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1001\/jama.2021.21392","article-title":"Contraception selection, effectiveness, and adverse effects: a review","volume":"326","author":"Teal","year":"2021","journal-title":"Jama"},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.contraception.2016.06.006","article-title":"Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States","volume":"94","author":"Upadhyay","year":"2016","journal-title":"Contraception"},{"key":"B26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/1471-0528.17331","article-title":"The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta\u2010analysis","volume":"130","author":"van Weelden","year":"2022","journal-title":"BJOG Int. J. Obstetrics and Gynaecol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.3390\/ijms24065814","article-title":"Hormone-related and drug-induced osteoporosis: a cellular and molecular overview","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1089\/jwh.2020.8989","article-title":"Bone mineral density changes associated with pregnancy, lactation, and medical treatments in premenopausal women and effects later in life","volume":"30","author":"Watts","year":"2021","journal-title":"J. Women\u2019s Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1080\/02648725.2023.2202541","article-title":"Propofol-associated serious adverse events: an analysis of the FAERS database","volume":"40","author":"Xuan","year":"2023","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e39055","DOI":"10.1097\/md.0000000000039055","article-title":"Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea:A retrospective study","volume":"103","author":"Yu","year":"2024","journal-title":"Medicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1472648","DOI":"10.3389\/fphar.2024.1472648","article-title":"Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1491032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:08:28Z","timestamp":1736158108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1491032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":32,"alternative-id":["10.3389\/fphar.2024.1491032"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1491032","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"article-number":"1491032"}}